Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | VCP | P55072 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | HPRT1 | P00492 | 12/20 | 0.66 |
| ▸ | TK1 | P04183 | 2/20 | 0.64 |
| ▸ | PNP | P00491 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | EDNRA | P25101 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | HBB | P68871 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiviciclovir SCHEMBL7745021 | 0.99 | BLM (0.66) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Omaciclovir SCHEMBL417577 | 0.92 | TK1 (0.62) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Omaciclovir SCHEMBL712427 | 0.92 | TK1 (0.62) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Omaciclovir SCHEMBL10507800 | 0.91 | TK1 (0.61) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL10506595 | 0.90 | TK1 (0.65) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL9172592 | 0.89 | HPRT1 (0.70) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Omaciclovir SCHEMBL571367 | 0.88 | HPRT1 (0.66) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL23710631 | 0.88 | HPRT1 (0.67) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| Penciclovir SCHEMBL3495 | 0.88 | TK1 (0.70) | BLMMEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL24420506 | 0.88 | HPRT1 (0.67) | BLMMEN1ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0948332-B1 | ANTIHERPETIC MEDICATED STICK CONTAINING ACYCLOVIR FOR TOPICAL APPLICATION | RECORDATI CHEM PHARM (CH) | 2003-09-03 | — | — | EP | claimed |
| EP-1019404-A4 | PURINE ACYCLONUCLEOSIDES AS ANTIVIRAL AGENTS | COMMW SCIENT IND RES ORG (AU) | 2001-07-04 | — | — | EP | claimed |
| EP-1019404-A1 | PURINE ACYCLONUCLEOSIDES AS ANTIVIRAL AGENTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-07-19 | — | — | EP | claimed |
| EP-0948332-A1 | ANTIHERPETIC PHARMACEUTICAL COMPOSITIONS CONTAINING ACYCLOVIR FOR TOPICAL APPLICATORS | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1999-10-13 | — | — | EP | claimed |
| WO-1999012927-A1 | PURINE ACYCLONUCLEOSIDES AS ANTIVIRAL AGENTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-03-18 | — | — | WO | claimed |
| WO-1998018472-A1 | ANTIHERPETIC PHARMACEUTICAL COMPOSITIONS CONTAINING ACYCLOVIR FOR TOPICAL APPLICATORS | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1998-05-07 | — | — | WO | claimed |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | INSIGNIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20100298256-A1 | ANTIVIRAL COMPOUNDS | EPIPHANY BIOSCIENCES, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298256-A1 | ANTIVIRAL COMPOUNDS | EPIPHANY BIOSCIENCES, INC. | 2010-11-25 | — | — | US | disclosed |
| WO-2009085267-A1 | ANTIVIRAL COMPOUNDS | EPIPHANY BIOSCIENCES (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-1019404-A4 | PURINE ACYCLONUCLEOSIDES AS ANTIVIRAL AGENTS | COMMW SCIENT IND RES ORG (AU) | 2001-07-04 | — | — | EP | disclosed |
| EP-1019404-A1 | PURINE ACYCLONUCLEOSIDES AS ANTIVIRAL AGENTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999012927-A1 | PURINE ACYCLONUCLEOSIDES AS ANTIVIRAL AGENTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | BLM 1124/4885MEN1 419/4885ALDH1A1 1423/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | BLM 595/4885MEN1 4821/4885ALDH1A1 1053/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | BLM 811/4885MEN1 2694/4885ALDH1A1 72/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | BLM 811/4885MEN1 2694/4885ALDH1A1 72/4885 |
| US-20100298256-A1 | ANTIVIRAL COMPOUNDS | MTAP, PNP, TYMP | BLM 1852/4885MEN1 3239/4885ALDH1A1 1707/4885 |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | ADRB3, ADRB2, ADRB1 | BLM 1987/4885MEN1 1013/4885ALDH1A1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.